12.49
price up icon4.00%   0.48
after-market Handel nachbörslich: 12.49
loading
Schlusskurs vom Vortag:
$12.01
Offen:
$11.78
24-Stunden-Volumen:
2.31M
Relative Volume:
2.76
Marktkapitalisierung:
$961.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-4.2054
EPS:
-2.97
Netto-Cashflow:
$-176.27M
1W Leistung:
-0.48%
1M Leistung:
+11.22%
6M Leistung:
+58.70%
1J Leistung:
+67.43%
1-Tages-Spanne:
Value
$11.43
$13.04
1-Wochen-Bereich:
Value
$11.19
$13.04
52-Wochen-Spanne:
Value
$4.92
$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name
Firmenname
Replimune Group Inc
Name
Telefon
(781) 222-9600
Name
Adresse
500 UNICORN PARK, WOBURN, MA
Name
Mitarbeiter
331
Name
Twitter
@Replimune
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
REPL
Replimune Group Inc
12.49 961.18M 0 -209.96M -176.27M -3.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-28 Eingeleitet ROTH MKM Buy
2023-04-17 Fortgesetzt Piper Sandler Overweight
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-10-15 Fortgesetzt BTIG Research Buy
2020-11-17 Eingeleitet BTIG Research Buy
2020-11-02 Eingeleitet Jefferies Buy
2020-10-15 Hochstufung H.C. Wainwright Neutral → Buy
2020-07-01 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-05 Eingeleitet Barclays Overweight
2019-09-04 Eingeleitet ROTH Capital Buy
2019-07-23 Eingeleitet Chardan Capital Markets Buy
2019-07-12 Hochstufung JP Morgan Neutral → Overweight
2019-07-08 Eingeleitet H.C. Wainwright Buy
2019-04-25 Eingeleitet Wedbush Outperform
2019-01-23 Herabstufung JP Morgan Overweight → Neutral
2018-08-14 Eingeleitet JP Morgan Overweight
2018-08-14 Eingeleitet Leerink Partners Outperform
Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

pulisher
Dec 20, 2024

Replimune Group (NASDAQ:REPL) Stock Price Up 8.2%Here's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 20, 2024
pulisher
Dec 18, 2024

Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Replimune CEO Sushil Patel sells $124,200 in company stock - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Replimune CEO Sushil Patel sells $124,200 in company stock By Investing.com - Investing.com UK

Dec 18, 2024
pulisher
Dec 18, 2024

Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Replimune Group (NASDAQ:REPL) Trading Down 4.7%Here's Why - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Dec 16, 2024
pulisher
Dec 15, 2024

Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 15, 2024

Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones - Investing.com India

Dec 15, 2024
pulisher
Dec 14, 2024

Replimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in November - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

Fmr LLC Sells 120,776 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 13, 2024
pulisher
Dec 13, 2024

Fmr LLC Has $6.87 Million Position in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Charles Schwab Investment Management Inc. Buys 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Charles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 13, 2024
pulisher
Dec 10, 2024

Jacobs Levy Equity Management Inc. Sells 44,153 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 10, 2024
pulisher
Dec 10, 2024

The Manufacturers Life Insurance Company Increases Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 10, 2024
pulisher
Dec 07, 2024

Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Average PT from Analysts - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

Intech Investment Management LLC Buys New Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Dec 06, 2024
pulisher
Dec 06, 2024

Where are the Opportunities in (REPL) - Stock Traders Daily

Dec 06, 2024
pulisher
Dec 05, 2024

Replimune Group, Inc. (NASDAQ:REPL) Holdings Reduced by Redmile Group LLC - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

Parkman Healthcare Partners LLC Buys 238,747 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

Replimune stock target raised to $19 on BLA submission By Investing.com - Investing.com Canada

Dec 03, 2024
pulisher
Dec 02, 2024

Baker BROS. Advisors LP Has $121.06 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Dec 02, 2024
pulisher
Dec 01, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Algert Global LLC - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Braidwell LP Acquires 2,057,460 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Replimune Group Announces Pricing of Public Offering - Defense World

Nov 29, 2024
pulisher
Nov 29, 2024

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch - Seeking Alpha

Nov 29, 2024
pulisher
Nov 28, 2024

Replimune Group Amends Sales Agreement with Leerink Partners LLC - Defense World

Nov 28, 2024
pulisher
Nov 26, 2024

Replimune reduces offering size in amended sales agreement - Investing.com

Nov 26, 2024
pulisher
Nov 26, 2024

Replimune reduces offering size in amended sales agreement By Investing.com - Investing.com Australia

Nov 26, 2024
pulisher
Nov 26, 2024

SEC Form 424B5 filed by Replimune Group Inc. - Quantisnow

Nov 26, 2024
pulisher
Nov 26, 2024

Cancer firm Replimune readies $125 million offering - The Pharma Letter

Nov 26, 2024
pulisher
Nov 26, 2024

REPLReplimune Group, Inc. Latest Stock News & Market Updates - StockTitan

Nov 26, 2024
pulisher
Nov 26, 2024

Replimune announces $125 million public offering By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 26, 2024

Replimune's SWOT analysis: stock outlook as RP1 nears key milestones By Investing.com - Investing.com Canada

Nov 26, 2024
pulisher
Nov 26, 2024

Replimune Announces Pricing of Upsized Public Offering - The Manila Times

Nov 26, 2024
pulisher
Nov 26, 2024

Replimune Prices $140M Upsized Public Offering of Common Stock & Warrants | REPL Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 25, 2024

Replimune's SWOT analysis: stock outlook as RP1 nears key milestones - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

How to Take Advantage of moves in (REPL) - Stock Traders Daily

Nov 25, 2024
pulisher
Nov 25, 2024

Replimune announces $125 million public offering - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Replimune Announces Proposed Public Offering - The Manila Times

Nov 25, 2024
pulisher
Nov 25, 2024

Canadian Dollar/Japanese Yen (CADJPY) QuotePress Release - The Globe and Mail

Nov 25, 2024
pulisher
Nov 25, 2024

Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World

Nov 25, 2024
pulisher
Nov 24, 2024

Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright - Defense World

Nov 24, 2024
pulisher
Nov 23, 2024

Replimune's stock surges 19% after-hours on FDA BLA submission - MSN

Nov 23, 2024
pulisher
Nov 23, 2024

Replimune Group (NASDAQ:REPL) Reaches New 52-Week High on Analyst Upgrade - MarketBeat

Nov 23, 2024
pulisher
Nov 23, 2024

BMO Capital Markets Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat

Nov 23, 2024
pulisher
Nov 23, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 23, 2024

Finanzdaten der Replimune Group Inc-Aktie (REPL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):